Methocaffequinate: A novel natural product-inspired multi-target antimalarial discovery platform

Seeking Strategic Investment, Research Collaboration, and Development Partnerships

Principal Investigator: Dr. Ayinla AbdulAziz Institution: Al-Hikmah University, Nigeria

Development Stage: Lead Discovery and Computational Validation Therapeutic Area: Malaria Drug Discovery

Executive Overview Malaria continues to impose a substantial health and economic burden across Africa and other endemic regions. While current therapies have saved millions of lives, the continued emergence of drug-resistant Plasmodium falciparum strains threatens long-term malaria control efforts. Our research has identified a promising new antimalarial lead, provisionally designated Methocaffequinate (A3), developed through the rational optimization of a naturally occurring plant-derived scaffold. The project has generated a computationally validated lead candidate with favorable drug-like properties and a predicted multi-target mechanism of action. The discovery represents a potential new direction in antimalarial drug development based on phenylpropanoid-derived chemistry rather than traditional antimalarial scaffolds

The Innovation What Makes Methocaffequinate Different? Methocaffequinate belongs to a class of optimized natural-product-inspired molecules designed to address limitations commonly associated with plant-derived compounds, including poor absorption and limited pharmaceutical suitability. The lead candidate demonstrates: Improved oral drug-likeness Favorable predicted bioavailability High predicted gastrointestinal absorption Compliance with key drug-likeness guidelines Predicted interaction with multiple malaria-associated molecular targets This combination is particularly attractive because multi-target agents may reduce the likelihood of rapid resistance development.